Global Antibody Drug Discovery Market Size, Share & Trends Analysis Report By Product (Primary & Secondary), By Methods (Hybridoma ,Phage Display , Transgenic Animal Based Method , Single B Cell Based Method), By Application (Infectious Diseases ,Immunolo

Global Antibody Drug Discovery Market Size, Share & Trends Analysis Report By Product (Primary & Secondary), By Methods (Hybridoma ,Phage Display , Transgenic Animal Based Method , Single B Cell Based Method), By Application (Infectious Diseases ,Immunology, Oncology , Stem cells, Neurobiology, Other Applications) By Technology (Immunohistochemistry , Immunofluorescence , Western Blotting, Flow Cytomystery , Immunoprecipitation , ELISA , Other Technologies ) By source ( Mouse, Rabbit, Goat and Other sources) Region and forecast till 2027.



Global Antibody Drug Discovery Market

From USD 16.1 billion in 2021 to USD 31.4 billion in 2027, the global Antibody Drug Discovery market is expected to grow at a CAGR of 14.3% over the forecast period. Growing pharmaceutical and biopharmaceutical R&D spending, rising demand for outsourced analytical testing services, initiatives for rare illness and orphan medication research, and the prohibitive cost of in-house drug development are all driving new income streams in the drug discovery services market. Stringent rules regulating drug research and animal testing, on the other hand, are projected to limit market growth to some extent. Drug discovery service companies have a problem due to a scarcity of trained employees.

Drivers: Growing R&D expenditure in the Pharma and Biopharma companies

The majority of pharmaceutical, biopharmaceutical, and medical device companies devote significant resources to the development of new drugs and devices. The pharmaceutical industry spends a lot of money on research and development. Pharmaceutical companies invest in research and development in order to bring high-quality, innovative products to market. Pharmaceutical and biopharmaceutical companies are opting for fully integrated or functional outsourcing Secondary for drug discovery and development, from the early development stage to the late-stage development phase, due to rising R&D spending. Outsourcing has emerged as a strategic alternative to overcome the lack of in-house resources required for new product development, as pharm a companies face enormous pressure to contain fixed costs. Big pharma is migrating to a leaner business model that heavily relies on outsourcing. This is evidenced by recent agreements between major pharmaceutical companies and contract research organizations (CROs) that provide drug discovery and development Secondary. Thus, rising pharmaceutical R&D spending boosts the market for drug discovery Secondary.

Restraints: High costs associated with the Antibody drug discovery.

Due to the general higher attrition rate of candidates during the development phase, drug discovery Secondary come at a high cost. Furthermore, clinical trials for rare disease research necessitate the recruitment of a specific candidate group. Furthermore, the success rate is extremely low, as is the number of approved drugs. This will be extremely expensive.

Impact of COVID-19

Countries' health systems are rapidly investing in research and development to combat the COVID-19 pandemic. CHEMBL, ZINC, FDA-approved drugs, and molecules in clinical trials were all screened for potential compounds. Drugs for the treatment of COVID-19 are being developed by screening both novel and existing drugs for their ability to alleviate symptoms and stop viral replication. As a result of the ongoing pandemic, the desire to find a cure for COVID-19 is expected to have a positive impact on the Antibody drug discovery market.

Segmentation By Product:

By Product the market is segmented into Primary & Secondary. The Primary sector will see a major growth in the market forecast period.

Segmentation By Methods:

Based On the category the market is segmented into Hybridoma, Phage Display, Transgenic Animal Based Method, Single B Cell Based Method. Phage Display will see a major growth in the market forecast period followed by Hybridoma.

Segmentation By Application:

Based on the application the market is segmented into Infectious Diseases, Immunology, Oncology, Stem cells, Neurobiology, Other Applications. Immunology sector will grow in the market forecast period and Infectious Diseases will also grow simultaneously.

Segmentation By technology:

Based on technology the market is segmented into Immunohistochemistry, Immunofluorescence, Western Blotting, Flow Cytomystery , Immunoprecipitation, ELISA, Other Technologies.

Segmentation By sources:

Based on the sources the market is segmented into Mouse, Rabbit, Goat and Other sources.

Segmentation by Region

Based on region, the NGS services market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for drug discovery services with an estimated share of by the year 2027. This can be attributed to the presence of well-established CROs, rising R&D expenditure by pharmaceutical & biopharmaceutical companies, rapid growth in the biosimilar and biologics markets, and the availability of the latest techniques, instruments, and facilities for drug discovery research in the region. Competitive Landscape:

The leading players in the Global antibody drug discovery market includes Berkeley Lights,10x Genomics ,Adimab, Hifi Boi , Biocytogen, Genscript ,Abveris , Lake Pharma, Charles River Wuxi Biologics, Twist Bioscience, Ligand and Evotech

Industrial Development:

Berkeley Lights, Inc., a leader in digital cell biology, and MImAbs SAS, an emerging CRO that discovers and develops antibodies for immunotechnology therapeutics and research, have announced the acquisition of the Berkeley Lights Beacon® system through a TechAccess subscription to help customers generate and validate novel therapeutic antibodies against cancer and inflammatory diseases.

In July 2018 10x Genomics collaborates with BioLegend and Immudex to broaden the research applications of its new single cell feature barcoding technology.

In May 2019 Adimab, LLC, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, has announced the expansion of an earlier collaboration with Novartis. Adimab will use its proprietary platform to discover and optimise antibodies against nine Novartis-selected targets, with the rights to develop and commercialise therapeutic programmes resulting from the collaboration.

Market taxonomy

Based on product

• Primary
• Secondary

• hybridoma
• Phage Display
• Transgenic Animal Based Method
• Single B Cell Based Method

• Infectious Diseases
• Immunology
• Oncology
• Stem cells
• Neurobiology
• Other Applications

• Immunohistochemistry
• Immunofluorescence
• Western Blotting
• Flow Cytomystery
• Immunoprecipitation
• ELISA
• Other Technologies

• Mouse
• Rabbit
• Goat
• Other sources

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa